Depressive symptoms in patients scheduled for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: Prospective associations with morbidity and mortality

Carissa A. Low, Dana H. Bovbjerg, Steven Ahrendt, Sara Alhelo, Haroon Choudry, Matthew Holtzman, Heather L. Jones, James F. Pingpank, Lekshmi Ramalingam, Herbert J. Zeh, Amer H. Zureikat, David L. Bartlett

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Purpose The current study examined prospective relationships between preoperative depressive symptoms and short-term (30-day morbidity and readmission) and long-term (overall survival) outcomes after hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (HIPEC + CS). Methods Ninety-eight patients scheduled for HIPEC + CS completed the Center for Epidemiologic Studies-Depression (CES-D) scale before surgery. Demographic and disease-specific factors and information about morbidity and readmission within 30 days after discharge were gathered from medical records. Survival was measured from date of surgery to death. Results Twenty-eight percent of patients had CES-D scores indicative of clinically significant depressive symptoms. Thirty-day morbidity occurred in 31.9% of patients and readmission in 22.2%. At the time of analysis (median follow-up of 49 months), 71.6% of patients were deceased, with median survival time of 11 months for those who died. After adjusting for relevant preoperative demographic and disease-specific factors, depressive symptoms were associated with greater odds of 30-day morbidity (n = 68; odds ratio, 5.50; 95% CI, 1.23 to 24.73; P = .03) and greater likelihood of 30-day readmission (n = 72; odds ratio, 5.92; 95% CI, 1.27 to 27.64; P = .02). Depressive symptoms were associated with shorter survival after adjustment for preoperative demographic and disease-specific factors (n = 87; hazard ratio, 1.88; 95% CI, 1.07 to 3.31; P = .03). This association was no longer significant when intraoperative/postoperative prognostic variables were added to the statistical model (n = 87; hazard ratio, 1.31; 95% CI, 0.72 to 2.37; P = .37). Conclusion Patients with clinically significant levels of preoperative depressive symptoms are at risk for poor clinical outcomes after HIPEC + CS, including greater risk of 30-day morbidity and readmission. Further research is warranted to determine biobehavioral mechanisms and examine whether effective interventions targeting preoperative depressive symptoms can reduce postoperative risk in this patient population.

Original languageEnglish (US)
Pages (from-to)1217-1222
Number of pages6
JournalJournal of Clinical Oncology
Volume34
Issue number11
DOIs
StatePublished - Apr 10 2016
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Depressive symptoms in patients scheduled for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: Prospective associations with morbidity and mortality'. Together they form a unique fingerprint.

  • Cite this

    Low, C. A., Bovbjerg, D. H., Ahrendt, S., Alhelo, S., Choudry, H., Holtzman, M., Jones, H. L., Pingpank, J. F., Ramalingam, L., Zeh, H. J., Zureikat, A. H., & Bartlett, D. L. (2016). Depressive symptoms in patients scheduled for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: Prospective associations with morbidity and mortality. Journal of Clinical Oncology, 34(11), 1217-1222. https://doi.org/10.1200/JCO.2015.62.9683